Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.30 |
| ▸ | TACR1 | P25103 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4430753 | 0.77 | HTR2A (0.36) | HTR2A | |
| SCHEMBL4432181 | 0.75 | HTR2A (0.39) | HTR2ACYP2D6 | |
| SCHEMBL17372634 | 0.74 | OPRM1 (0.33) | HTR2ASLC6A4TACR1CYP2D6SLC6A2 | |
| SCHEMBL16915168 | 0.64 | PKM (0.36) | TACR1 | |
| SCHEMBL6002896 | 0.62 | HTR2A (0.38) | HTR2ASLC6A4TACR1KCNH2 | |
| SCHEMBL11287253 | 0.60 | OPRM1 (0.38) | HTR2ASLC6A4CYP2D6SLC6A2KCNH2 | |
| SCHEMBL16151035 | 0.60 | SIGMAR1 (0.46) | — | |
| SCHEMBL27449591 | 0.60 | LMNA (0.35) | HTR2A | |
| SCHEMBL5915123 | 0.59 | OPRM1 (0.39) | HTR2ASLC6A4KCNH2 | |
| SCHEMBL28775360 | 0.59 | HTR2A (0.53) | HTR2ASLC6A4TACR1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | HTR2A 4298/4885SLC6A4 529/4885TACR1 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.